Clinical Practice Guidelines for diagnosis of organic involvement in amyloidosis: Part 3/3 Year 2020: CPG organic damage in amyloidosis
Method: Use the PICO format to generate a series of questions, focusing on the specificity and sensitivity of the amyloidosis diagnostic test. PubMed searches were conducted in English and Spanish from July to August 2019. The level of evidence and recommendation are based on the GRADE system (http:...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2022
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/30903 |
| Aporte de: |
| id |
I10-R327-article-30903 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
amyloidosis diagnosis inmunoglobulin light-chain amyloidosis amyloidosis, familial amiloidosis diagnóstico amiloidosisamiloidosis de cadenas ligeras de las inmunoglobulinas amiloidosis familiar amiloidose diagnóstico amiloidoseamiloidose de cadeia leve de imunoglobulina amiloidose familiar |
| spellingShingle |
amyloidosis diagnosis inmunoglobulin light-chain amyloidosis amyloidosis, familial amiloidosis diagnóstico amiloidosisamiloidosis de cadenas ligeras de las inmunoglobulinas amiloidosis familiar amiloidose diagnóstico amiloidoseamiloidose de cadeia leve de imunoglobulina amiloidose familiar Posadas Martinez, Maria Lourdes Aguirre, María Adela Greloni, Gustavo Marciano, Sebastian Perez de Arenaza, Diego Rugiero, Marcelo Tomei, Mauricio Peuchot, Veronica Nucifora, Elsa Aparicio, Lucas Sebastián Leon Cejas, Luciana Luxardo, Rosario Popelka, Paula Reisin, Ricardo Seilikovivh, Pamela Varela, Carlos Federico Clinical Practice Guidelines for diagnosis of organic involvement in amyloidosis: Part 3/3 Year 2020: CPG organic damage in amyloidosis |
| topic_facet |
amyloidosis diagnosis inmunoglobulin light-chain amyloidosis amyloidosis, familial amiloidosis diagnóstico amiloidosisamiloidosis de cadenas ligeras de las inmunoglobulinas amiloidosis familiar amiloidose diagnóstico amiloidoseamiloidose de cadeia leve de imunoglobulina amiloidose familiar |
| author |
Posadas Martinez, Maria Lourdes Aguirre, María Adela Greloni, Gustavo Marciano, Sebastian Perez de Arenaza, Diego Rugiero, Marcelo Tomei, Mauricio Peuchot, Veronica Nucifora, Elsa Aparicio, Lucas Sebastián Leon Cejas, Luciana Luxardo, Rosario Popelka, Paula Reisin, Ricardo Seilikovivh, Pamela Varela, Carlos Federico |
| author_facet |
Posadas Martinez, Maria Lourdes Aguirre, María Adela Greloni, Gustavo Marciano, Sebastian Perez de Arenaza, Diego Rugiero, Marcelo Tomei, Mauricio Peuchot, Veronica Nucifora, Elsa Aparicio, Lucas Sebastián Leon Cejas, Luciana Luxardo, Rosario Popelka, Paula Reisin, Ricardo Seilikovivh, Pamela Varela, Carlos Federico |
| author_sort |
Posadas Martinez, Maria Lourdes |
| title |
Clinical Practice Guidelines for diagnosis of organic involvement in amyloidosis: Part 3/3 Year 2020: CPG organic damage in amyloidosis |
| title_short |
Clinical Practice Guidelines for diagnosis of organic involvement in amyloidosis: Part 3/3 Year 2020: CPG organic damage in amyloidosis |
| title_full |
Clinical Practice Guidelines for diagnosis of organic involvement in amyloidosis: Part 3/3 Year 2020: CPG organic damage in amyloidosis |
| title_fullStr |
Clinical Practice Guidelines for diagnosis of organic involvement in amyloidosis: Part 3/3 Year 2020: CPG organic damage in amyloidosis |
| title_full_unstemmed |
Clinical Practice Guidelines for diagnosis of organic involvement in amyloidosis: Part 3/3 Year 2020: CPG organic damage in amyloidosis |
| title_sort |
clinical practice guidelines for diagnosis of organic involvement in amyloidosis: part 3/3 year 2020: cpg organic damage in amyloidosis |
| description |
Method: Use the PICO format to generate a series of questions, focusing on the specificity and sensitivity of the amyloidosis diagnostic test. PubMed searches were conducted in English and Spanish from July to August 2019. The level of evidence and recommendation are based on the GRADE system (http://www.gradeworkinggroup.org/index.htm). The recommendations are graded according to their direction (for or against) and strength (strong and weak). Finally, it is recommended to use GLIA tools to evaluate the obstacles and facilitators in implementation.
Suggested explanation: A strong suggestion indicates a high degree of trust in support or opposition to the intervention. When defining a strong recommendation, this guide uses the "recommended" language. The weaker recommendations indicate that the outcome of the intervention (favorable or unfavorable) is doubtful. In this case, if a weak recommendation is defined, the "recommendation" language is used.
How to use these guidelines: Recommendations must be explained within the scope of special care in validated diagnostic studies conducted by specially trained doctors. It is not assumed to change the coexistence conditions of the disease process. Presumably, the attending physician has a high degree of suspicion of amyloidosis. It assumes that diagnostic research is conducted by well-trained doctors using a validated standardized method. This guide is intended for health care professionals and those involved in health care policies to help ensure that the necessary agreements have been reached to provide appropriate care.
Summary of recommendations
For patients with suspected amyloidosis, it is recommended:
Measured value of creatinine be used as a preliminary assessment for the diagnosis of renal involvement in patients with suspected renal amyloidosis.
24-hour proteinuria be measured and characterized to diagnose renal involvement in patients with suspected renal amyloidosis.
Immunohistochemical staining of skin biopsy for patients genetically diagnosed with ATTR, for early diagnosis of neuropathy. The signs or symptoms of these patients suggest the presence of fine fiber neuropathy.
Skin biopsy and immunohistochemical staining for early diagnosis of neuropathy. These patients show signs or symptoms suggesting fine fiber neuropathy.
Conduct nerve conduction studies on motor and sensory fibers to diagnose total fiber neuropathy in patients who are diagnosed or suspected of having amyloidosis.
Test (Sudoscan) is recommended for the early diagnosis of peripheral autonomic neuropathy (even in asymptomatic patients) in patients with suspected autonomic neuropathy due to amyloidosis.
Ewing's standard to measure heart rate variability to diagnose autonomic hypofunction in patients with autonomic neuropathy suspected of having amyloidosis.
Measure orthostatic hypotension to diagnose early autonomic hypotension for patients with amyloidosis or systemic amyloidosis suspected of autonomic neuropathy.
It is suggested:
QST test to diagnose neuropathy early for patients genetically diagnosed with ATTR, if they show signs or symptoms suggesting fine fiber neuropathy
Measure alkaline phosphatase to initially assess liver involvement in patients with amyloidosis.
|
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2022 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/30903 |
| work_keys_str_mv |
AT posadasmartinezmarialourdes clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT aguirremariaadela clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT grelonigustavo clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT marcianosebastian clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT perezdearenazadiego clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT rugieromarcelo clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT tomeimauricio clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT peuchotveronica clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT nuciforaelsa clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT apariciolucassebastian clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT leoncejasluciana clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT luxardorosario clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT popelkapaula clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT reisinricardo clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT seilikovivhpamela clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT varelacarlosfederico clinicalpracticeguidelinesfordiagnosisoforganicinvolvementinamyloidosispart33year2020cpgorganicdamageinamyloidosis AT posadasmartinezmarialourdes guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT aguirremariaadela guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT grelonigustavo guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT marcianosebastian guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT perezdearenazadiego guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT rugieromarcelo guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT tomeimauricio guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT peuchotveronica guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT nuciforaelsa guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT apariciolucassebastian guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT leoncejasluciana guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT luxardorosario guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT popelkapaula guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT reisinricardo guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT seilikovivhpamela guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT varelacarlosfederico guiadepracticaclinicaparaeldiagnosticodecompromisoorganicoenamiloidosisparte33ano2020gpccompromisoorganicoenamiloidosis AT posadasmartinezmarialourdes guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT aguirremariaadela guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT grelonigustavo guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT marcianosebastian guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT perezdearenazadiego guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT rugieromarcelo guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT tomeimauricio guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT peuchotveronica guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT nuciforaelsa guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT apariciolucassebastian guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT leoncejasluciana guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT luxardorosario guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT popelkapaula guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT reisinricardo guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT seilikovivhpamela guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose AT varelacarlosfederico guiadepraticaclinicaparaodiagnosticodeenvolvimentoorganicodaamiloidoseparte33ano2020gpccompromissoorganiconaamiloidose |
| first_indexed |
2024-09-03T21:02:11Z |
| last_indexed |
2024-09-03T21:02:11Z |
| _version_ |
1809210232681791488 |
| spelling |
I10-R327-article-309032023-03-20T16:24:58Z Clinical Practice Guidelines for diagnosis of organic involvement in amyloidosis: Part 3/3 Year 2020: CPG organic damage in amyloidosis Guía de Práctica Clínica para el diagnóstico de compromiso orgánico en amiloidosis: Parte 3/3 Año 2020: GPC compromiso orgánico en amiloidosis Guia de prática clínica para o diagnóstico de envolvimento orgânico da amiloidose: Parte 3/3 Ano 2020: GPC compromisso orgânico na amiloidose Posadas Martinez, Maria Lourdes Aguirre, María Adela Greloni, Gustavo Marciano, Sebastian Perez de Arenaza, Diego Rugiero, Marcelo Tomei, Mauricio Peuchot, Veronica Nucifora, Elsa Aparicio, Lucas Sebastián Leon Cejas, Luciana Luxardo, Rosario Popelka, Paula Reisin, Ricardo Seilikovivh, Pamela Varela, Carlos Federico amyloidosis diagnosis inmunoglobulin light-chain amyloidosis amyloidosis, familial amiloidosis diagnóstico amiloidosisamiloidosis de cadenas ligeras de las inmunoglobulinas amiloidosis familiar amiloidose diagnóstico amiloidoseamiloidose de cadeia leve de imunoglobulina amiloidose familiar Method: Use the PICO format to generate a series of questions, focusing on the specificity and sensitivity of the amyloidosis diagnostic test. PubMed searches were conducted in English and Spanish from July to August 2019. The level of evidence and recommendation are based on the GRADE system (http://www.gradeworkinggroup.org/index.htm). The recommendations are graded according to their direction (for or against) and strength (strong and weak). Finally, it is recommended to use GLIA tools to evaluate the obstacles and facilitators in implementation. Suggested explanation: A strong suggestion indicates a high degree of trust in support or opposition to the intervention. When defining a strong recommendation, this guide uses the "recommended" language. The weaker recommendations indicate that the outcome of the intervention (favorable or unfavorable) is doubtful. In this case, if a weak recommendation is defined, the "recommendation" language is used. How to use these guidelines: Recommendations must be explained within the scope of special care in validated diagnostic studies conducted by specially trained doctors. It is not assumed to change the coexistence conditions of the disease process. Presumably, the attending physician has a high degree of suspicion of amyloidosis. It assumes that diagnostic research is conducted by well-trained doctors using a validated standardized method. This guide is intended for health care professionals and those involved in health care policies to help ensure that the necessary agreements have been reached to provide appropriate care. Summary of recommendations For patients with suspected amyloidosis, it is recommended: Measured value of creatinine be used as a preliminary assessment for the diagnosis of renal involvement in patients with suspected renal amyloidosis. 24-hour proteinuria be measured and characterized to diagnose renal involvement in patients with suspected renal amyloidosis. Immunohistochemical staining of skin biopsy for patients genetically diagnosed with ATTR, for early diagnosis of neuropathy. The signs or symptoms of these patients suggest the presence of fine fiber neuropathy. Skin biopsy and immunohistochemical staining for early diagnosis of neuropathy. These patients show signs or symptoms suggesting fine fiber neuropathy. Conduct nerve conduction studies on motor and sensory fibers to diagnose total fiber neuropathy in patients who are diagnosed or suspected of having amyloidosis. Test (Sudoscan) is recommended for the early diagnosis of peripheral autonomic neuropathy (even in asymptomatic patients) in patients with suspected autonomic neuropathy due to amyloidosis. Ewing's standard to measure heart rate variability to diagnose autonomic hypofunction in patients with autonomic neuropathy suspected of having amyloidosis. Measure orthostatic hypotension to diagnose early autonomic hypotension for patients with amyloidosis or systemic amyloidosis suspected of autonomic neuropathy. It is suggested: QST test to diagnose neuropathy early for patients genetically diagnosed with ATTR, if they show signs or symptoms suggesting fine fiber neuropathy Measure alkaline phosphatase to initially assess liver involvement in patients with amyloidosis. Métodos: Se generó un listado de preguntas con el formato PICO centradas en la especificidad y sensibilidad de las pruebas diagnósticas en amiloidosis. Se realizó la búsqueda en PubMed durante julio-agosto del 2019, en inglés y español. Los niveles de evidencia y los grados de recomendación se basan en el sistema GRADE (http://www.gradeworkinggroup.org/index.htm). Las recomendaciones se graduaron según su dirección (a favor o en contra) y según fuerza (fuertes y débiles). Las recomendaciones finales fueron evaluadas con la herramienta GLIA para barreras y facilitadores en la implementación de éstas. Interpretación de recomendaciones: Las recomendaciones fuertes indican alta confianza, ya sea a favor o en contra, de una intervención. En esta guía se utiliza el lenguaje “se recomienda” cuando se define una recomendación fuerte. Las recomendaciones débiles indican que los resultados para una intervención, favorable o desfavorable, son dudosos. En este caso, se utiliza el lenguaje “se sugiere”, cuando se define una recomendación débil. Cómo utilizar estas pautas: Las recomendaciones deben ser interpretadas en el contexto de la atención especializada, con estudios diagnósticos validados y realizados por médicos entrenados. Se asume que el médico tratante tiene alto nivel de sospecha de amiloidosis. No asume condiciones coexistentes que modifican el curso de la enfermedad. Asume que los estudios diagnósticos son realizados por médicos entrenados con métodos validados y estandarizados. Esta guía es relevante para los profesionales de la salud y los involucrados en las políticas sanitarias, para ayudar a asegurar que existan los acuerdos necesarios para brindar la atención adecuada. Resumen de recomendaciones En pacientes con sospecha de amiloidosis se recomienda: Medición de la creatinina como evaluación inicial para el diagnóstico del compromiso renal en el paciente con sospecha de amiloidosis renal. Medición y caracterización de la proteinuria de 24 hs para el diagnóstico de compromiso renal en pacientes con sospecha de amiloidosis renal. Biopsia de piel con tinción inmunohistoquímica para el diagnóstico precoz de neuropatía en pacientes con diagnóstico genético de ATTR, que presenten signos o síntomas sugestivos de neuropatía de fibra fina. Biopsia de piel con tinción inmunohistoquímica para el diagnóstico precoz de neuropatía en pacientes con sospecha de amiloidosis, que presenten signos o síntomas sugestivos de neuropatía de fibra fina. Estudios de conducción nerviosa evaluando fibras motoras y sensitivas para el diagnóstico de neuropatía de fibras gruesas en pacientes con diagnóstico o sospecha de amiloidosis. Prueba de QST para el diagnóstico precoz de neuropatía en pacientes con diagnóstico genético de ATTR, que presenten signos o síntomas sugestivos de neuropatía de fibras finas. Test de cuantificación sudorípara (Sudoscan) para diagnóstico precoz de neuropatía autonómica periférica (incluso en asintomáticos) en pacientes con sospecha de neuropatía autonómica por amiloidosis. Medición de la variabilidad de la frecuencia cardiaca con criterios de Ewing para el diagnóstico de disautonomía en pacientes con sospecha de neuropatía autonómica por amiloidosis. Medición de hipotensión ortostática con técnica adecuadamente estandarizada para el diagnóstico precoz de compromiso autonómico en el paciente con sospecha de neuropatía autonómica por amiloidosis o diagnóstico de amiloidosis sistémica Se sugiere: Prueba de QST para el diagnóstico precoz de neuropatía en pacientes con amiloidosis o sospecha de amiloidosis, que presenten signos o síntomas sugestivos de neuropatía de fibras finas. Medición de fosfatasa alcalina para evaluación inicial del compromiso hepático en el paciente con amiloidosis. Method: Replace the various forms of PICO with specific testes. Giulio bus companies before 2019, Spain and Spain. The grade certificate recommended to your system (http://www.gradeworkinggroup.org/index.htm). As the recommended classification criteria, it is recommended to you (recommended or opposed) and recommended to you (recommended to you). As recommended by FINA, it is Ferramenta, which is composed of GLIA para barreiras e facilitadores em sua Implementação. Explicação sugerida: uma sugestão forte indica um alto nível de confiança no apoio ou oposição à intervenção. Ao definir recomendações fortes, este guia usa uma linguagem "recomendada". As recomendações mais fracas indicam que o resultado da intervenção (favorável ou desfavorável) é duvidoso. Nesse caso, se uma recomendação fraca for definida, a linguagem de "recomendação" será usada. Como usar essas diretrizes: As recomendações devem ser explicadas no contexto de cuidados especializados e estudos de diagnóstico validados realizados por médicos treinados. Não tem como premissa condições de coexistência que modificarão o curso da doença. Suponha que o médico assistente suspeite de um alto nível de amiloidose. Ele presumiu que a pesquisa diagnóstica foi conduzida por médicos bem treinados usando métodos padronizados validados. Este guia se aplica a profissionais de saúde e todos os envolvidos na política de saúde para ajudar a garantir que os arranjos necessários sejam feitos para fornecer cuidados adequados. Resumo das recomendações Em pacientes com suspeita de amiloidose, é recomendado Medido da creatinina seja usado como uma avaliação preliminar para o diagnóstico de envolvimento renal em pacientes com suspeita de amiloidose renal. Dosagem e as características da proteinúria de 24 horas sejam usadas para diagnosticar o envolvimento renal em pacientes com suspeita de amiloidose renal. Para pacientes com diagnóstico genético de ATTR, a coloração imunohistoquímica da biópsia de pele é recomendada para o diagnóstico precoce de neuropatia.Os sinais ou sintomas desses pacientes indicam a presença de neuropatia de fibra fina. Biópsia de pele e coloração imunohistoquímica para pacientes com suspeita de amiloidose para o diagnóstico precoce de neuropatia. Esses pacientes apresentam sinais ou sintomas sugestivos de neuropatia fibrilar. Condução nervosa das fibras motoras e sensoriais para diagnosticar ou suspeitar de amiloidose. Para pacientes com diagnóstico genético de ATTR, se os sinais ou sintomas indicarem a presença de neuropatia de fibra fina, é recomendado o uso do teste QST para o diagnóstico precoce de neuropatia. Teste quantitativo do suor (Sudoscan) é recomendado para neuropatia autonômica periférica (mesmo assintomáticos) em pacientes com suspeita de neuropatia autonômica por amiloidose. Padrão de Ewing para medir a variabilidade da frequência cardíaca a fim de diagnosticar anormalidades autonômicas. Medir a hipotensão ortostática por meio de técnicas padronizadas adequadas para o diagnóstico precoce de disfunção autonômica em pacientes com suspeita de neuropatia autonômica ou amiloidose sistêmica causada por amiloidose. Sugere-se: Teste QST é recomendado para o diagnóstico precoce de neuropatia para pacientes com amiloidose ou suspeita de amiloidose, se seus sinais ou sintomas indicarem a presença de neuropatia de fibra fina, Medir a fosfatase alcalina para avaliar inicialmente o envolvimento do fígado em pacientes com amiloidose. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2022-12-21 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion text/html text/html text/html text/html application/pdf text/html text/html https://revistas.unc.edu.ar/index.php/med/article/view/30903 10.31053/1853.0605.v79.n4.30903 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 79 No. 4 (2022); 391-399 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 79 Núm. 4 (2022); 391-399 Revista da Faculdade de Ciências Médicas de Córdoba; v. 79 n. 4 (2022); 391-399 1853-0605 0014-6722 10.31053/1853.0605.v79.n4 spa https://revistas.unc.edu.ar/index.php/med/article/view/30903/39171 https://revistas.unc.edu.ar/index.php/med/article/view/30903/39185 https://revistas.unc.edu.ar/index.php/med/article/view/30903/39187 https://revistas.unc.edu.ar/index.php/med/article/view/30903/39188 https://revistas.unc.edu.ar/index.php/med/article/view/30903/39971 https://revistas.unc.edu.ar/index.php/med/article/view/30903/39164 https://revistas.unc.edu.ar/index.php/med/article/view/30903/39167 Derechos de autor 2022 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |